Carolina R C Pieterman
Overview
Explore the profile of Carolina R C Pieterman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Vliembergen E, Pieterman C, van de Ven A, Braat A, Valk G, de Laat J
Endocr Oncol
. 2025 Feb;
5(1):e240050.
PMID: 39949334
Pancreatic neuroendocrine tumours (PanNETs) significantly impact life expectancy in multiple endocrine neoplasia type 1 (MEN1). Both solid and cystic pancreatic lesions are observed in MEN1, yet limited research has been...
2.
Ballaro R, Wasylishen A, Pieterman C, Olsen C, Irajizad E, Wu R, et al.
Cancer Lett
. 2025 Feb;
614:217537.
PMID: 39924079
Metastatic duodenopancreatic neuroendocrine tumors (dpNETs) are the primary cause of mortality among patients with Multiple Endocrine Neoplasia Type 1 (MEN1). Emerging evidence implicates the microbiome and microbial-derived secreted factors in...
3.
Pieterman C, Grozinsky-Glasberg S, OToole D, Howe J, Ambrosini V, Belli S, et al.
J Neuroendocrinol
. 2024 Nov;
37(1):e13468.
PMID: 39587981
Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation...
4.
Clemente-Gutierrez U, Pieterman C, Lui M, Szabo Yamashita T, Tame-Elorduy A, Huang B, et al.
Endocr Relat Cancer
. 2023 Dec;
31(2).
PMID: 38108666
Adrenal lesions (ALs) are often detected in patients with multiple endocrine neoplasia type 1 (MEN1). However, they are not well described in MEN1, making their clinical management unclear. This study...
5.
Fahrmann J, Wasylishen A, Pieterman C, Irajizad E, Vykoukal J, Wu R, et al.
J Clin Endocrinol Metab
. 2023 Jun;
108(12):3260-3271.
PMID: 37307230
Purpose: Patients with multiple endocrine neoplasia type 1 (MEN1) are predisposed to develop duodenopancreatic neuroendocrine tumors (dpNETs), and metastatic dpNET is the primary cause of disease-related mortality. Presently, there is...
6.
Van Beek D, Verschuur A, Brosens L, Valk G, Pieterman C, Vriens M
Surg Oncol Clin N Am
. 2023 Mar;
32(2):343-371.
PMID: 36925190
Pancreatic neuroendocrine tumors (PNETs) occur in < 1/100,000 patients and most are nonfunctioning (NF). Approximately 5% occur as part of multiple endocrine neoplasia type 1. Anatomic and molecular imaging have...
7.
Van Beek D, Pieterman C, Wessels F, van de Ven A, de Herder W, Dekkers O, et al.
Front Endocrinol (Lausanne)
. 2022 Oct;
13:926491.
PMID: 36277719
Background: In multiple endocrine neoplasia type 1 (MEN1), pancreatic neuroendocrine tumors (PanNETs) have a high prevalence and represent the main cause of death. This study aimed to assess the diagnostic...
8.
Landry J, Clemente-Gutierrez U, Pieterman C, Chiang Y, Waguespack S, Jimenez C, et al.
Surgery
. 2022 Apr;
172(2):559-566.
PMID: 35437162
Background: Neuroendocrine tumors can cause ectopic Cushing syndrome, and most patients have metastatic disease at diagnosis. We identified risk factors for outcome, evaluated ectopic Cushing syndrome management, and explored the...
9.
Pieterman C, Valk G
Clin Endocrinol (Oxf)
. 2022 Mar;
97(4):409-423.
PMID: 35319130
This review provides an overview of novel insights in the clinical management of patients with Multiple Endocrine Neoplasia Type 1, focusing on the last decade since the last update of...
10.
Landry J, Pieterman C, Clemente-Gutierrez U, Grubbs E, Fisher S, Graham P, et al.
Surgery
. 2021 Dec;
171(5):1240-1246.
PMID: 34952716
Background: Postoperative hypoparathyroidism from inadequate parathyroid hormone is of concern after multigland resections in multiple endocrine neoplasia type 1-related primary hyperparathyroidism. We evaluated risk factors, long-term outcomes, and roles of...